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Abstract   24 
 25 
Objectives 26 
Cats are commonly affected by chronic kidney disease (CKD). Many of the 27 
reactive carbonyl intermediates and end-products originating from the oxidative 28 
stress pathways are recognized as uremic toxins and may play a role in the 29 
progression of chronic renal failure. The aim of the present study is to confirm 30 
whether carbonyl stress and end product formation are higher in cats affected by 31 
CKD than in healthy cats and to assess whether angiotensin-converting-enzyme 32 
(ACE) inhibitors might affect these hallmarks.  33 
 34 
Methods 35 
Twenty-two cats were matched according to age and body condition score (BSC) 36 
and divided into three groups: control group (CG; n = 6), cats with chronic kidney 37 
disease (CKD; n = 11) and cats with chronic kidney disease treated with 38 
angiotensin-converting-enzyme (ACE) inhibitors (ACE; n = 5). Serum analysis 39 
was carried out to measure the levels of Pentosidine, Carboxymethyllysine, 40 
Advanced Oxidation Protein Products, Malondialdehyde, Methylglyoxal and 41 
Hexanoyl-Lysine. In addition, blood urea, creatinine, triglycerides, potassium, 42 
phosphorous, total proteins, glucose, urine protein to creatinine ratio and arterial 43 
systemic pressure were also evaluated. After checking for normality, 44 
comparisons between groups were performed followed by multiple‐comparison 45 
tests. P values ≤0.05 were considered significant. Correlations between plasma 46 
 3 
concentrations of the considered biomarkers and of the other metabolic 47 
parameters were investigated using Spearman’s correlation coefficient. 48 
 49 
Results (P) 50 
Advanced oxidation protein products, malondialdehyde and hexanoyl-lysine 51 
concentrations were significantly higher in CKD and ACE treated groups 52 
compared with the control group (P < 0.05). The ACE group showed an increase 53 
in the levels of carboxymethyllysine when compared with the control group, 54 
whereas intermediate values of these biomarkers were found in the CKD group 55 
(P < 0.05). The highest values of carboxymethyllysine, advanced oxidation 56 
protein products and hexanoyl-lysine were found in the ACE treated group. By 57 
contrast, the CKD group showed the highest concentration of malondialdehyde. 58 
No statistically significant difference was found in the levels of pentosidine or 59 
methylglyoxal. Carbonyl stress and end-product formation correlated with 60 
creatinine and urea and with each other. Neither pentosidine nor methylglyoxal 61 
showed any correlation with other uremic toxins. 62 
 63 
Conclusions and relevance 64 
Significantly high concentrations of both intermediates and "end products" of 65 
carbonyl/oxidative stress, which are also uremic toxins, were detected in CKD 66 
cats. To date, the present study is the first to have concurrently taken into 67 
account several uremic toxins and biochemical parameters in cats affected by 68 
chronic kidney disease.   69 
 4 
 70 
Introduction 71 
 72 
The term “chronic kidney disease” (CKD) indicates an irreversible decrease in 73 
renal function, due to structural or functional defects in one or both kidneys.1,2 74 
Cats, especially in geriatric age, are commonly affected by CKD.3,4 In human 75 
medicine, it has been shown that oxidative stress (OS) is associated with uremia.5 76 
It has been hypothesized that two main events occur in CKD: the facilitation of 77 
inflammation and oxidative stress6 by uremic toxins: and the impairment of 78 
antioxidant enzymes in uremia.7,8 To our knowledge, only four studies evaluated 79 
oxidative stress in cats diagnosed with CKD: Yu and Paetau-Robinson9 80 
conducted research on oxidative stress and the effects of dietary antioxidant 81 
supplementation; Keegan and Webb 10 correlated oxidative stress parameters 82 
with neutrophil function; Krofic Zel et al11 evaluated the activity of antioxidant 83 
systems; and Whitehouse et al12 investigated the increase in urinary F2-84 
Isoprostanes in different International Renal Interest Society (IRIS) stages of 85 
CKD.  86 
OS is a complex phenomenon, which includes many pathways. Although 87 
it can be measured in different ways, the assessment of the by-products of OS 88 
reactions by means of biomolecules, like proteins, lipids and sugars, is the most 89 
common procedure. When reactive species act on lipids many peroxidation 90 
products are created, such as hydroperoxides, conjugated dienes, isoprostanes 91 
and derived carbonyls, such as malondialdehyde (MDA) and hydroxynonenal 92 
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(HNE).13 It has recently been shown that hexanoyl-lysine (HEL), another marker 93 
of fatty acid oxidation, is formed at an earlier stage of the cascade. This 94 
compound is a specific marker of omega-6 oxidation and promotes the formation 95 
of adducts from linoleic acid or arachidonic acid.14 Proteins are other molecules 96 
sensitive to the action of reactive species. Amino acids (AA) are prone to many 97 
reactions, including hydroxylation, nitration, sulphoxidation, chlorination, cross-98 
linking and conversion to carbonyl derivatives.13 99 
Of all the by-products originating from proteins damaged by OS, 100 
carbonyls, advanced oxidation protein products (AOPP) and adducts formed 101 
between AA and free carbonyls or lipid oxidation/reducing sugar products are 102 
the most extensively studied.13 The latter group of reactions consists of the 103 
addition of compounds deriving from glycation and lipid peroxidation to 104 
proteins:15 these reactions are also known as carbonylation. This modification is 105 
sustained by a surplus of reactive carbonyl compounds; in this circumstance, a 106 
series of different complex reactions lead to the formation of more stable final 107 
products, called “advanced end-products”, such as pentosidine (Pent) and 108 
carboxymethyllysine (CML). While Pent is a marker of the glycoxidative cascade 109 
and can be classified as an advanced glycation end product (AGE), CML is not 110 
only formed along this pathway but also during the lipoxidation cascade; thus, 111 
CML can also be considered an advanced lipoxidation end product (ALE) 112 
compound.16 An increase in these reactions is referred to as carbonyl stress and 113 
is related to the pathogenesis of several diseases, including chronic renal failure.17 114 
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From this brief summary, it is clear that OS creates a series of reactions 115 
leading to measurable by- and end-products; what it is known in human 116 
medicine is that reactive oxygen species (ROS) increase carbonyl stress18 and 117 
facilitate the formation of end-products, which themselves act as inducers of ROS 118 
in a vicious cycle (Figure 1). This tight relationship is present in uremic human 119 
patients affected by CKD, who show an increase in both carbonyl and oxygen 120 
reactive species.5,7 These molecules are recognized as uremic toxins and may play 121 
a role in the progression of chronic renal failure.  122 
Over recent years, research into uremic toxicity has highlighted dozens of 123 
retention solutes that interact negatively with physiological mechanisms.19 124 
Looking at the uremic database,20 the only uremic toxins studied in feline 125 
medicine are creatinine (used for IRIS staging[???]), urea and MDA.9 126 
Understanding how these substances are formed in chronic diseases can lead to 127 
the development of new therapeutic strategies. Currently, in cats affected by 128 
CKD, the main therapeutic goal attempts to reduce the progression of the 129 
disease.21 To date, the available approaches are based on the administration of 130 
proper diets (with the essential nutritional characteristics established by the 131 
Commission Regulation (EU) No 1123/2014) consisting of high quality proteins 132 
in reduced quantity and restricted levels of phosphorous). Moreover, according 133 
to other sources, this dietary regime should be supplemented with n-3 PUFA and 134 
antioxidants, dehydration should be corrected and drugs (such as calcium 135 
channel blockers and inhibitors of the renin-angiotensin-aldosterone system, i.e. 136 
angiotensin converting enzyme inhibitors-ACE or angiotensin receptor blockers 137 
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ARB)22 introduced to improve renal function, reduce blood pressure, and lower 138 
systemic oxidative stress.21 With regard to this last clinical recommendation, we 139 
previously reported that oral antihypertensive therapy exerts antioxidant 140 
activity, which scavenges reactive oxygen species in humans.23 141 
The aim of the present study is to confirm whether in cats affected by 142 
CKD, carbonyl stress and end product formation are higher than in healthy cats 143 
and to assess whether ACE inhibitors may affect these hallmarks.  144 
 145 
Materials and Methods 146 
Selection of cases 147 
The study was carried out between January 2013 and June 2014. Twenty-two 148 
adults cats (9 neutered males and 13 neutered females) aged 4 to 14 years were 149 
enrolled. For each cat, a complete anamnesis was obtained and a physical 150 
examination, complete blood count (CBC), serum biochemistry and urinalysis 151 
performed. Residual samples from routine visits not related to the study were 152 
employed. Cat owners gave their consent to the use of surplus samples after 153 
routine testing. 154 
The cats were divided into three groups: controls: CKD: and ACE.  155 
Animals comprising the control group (CG, n = 6) were enrolled during annual 156 
check-up examinations; the inclusion criteria for control animals were based on 157 
their clinical history and the absence of any disease on the basis of their 158 
anamnesis, physical examination, blood and urine analyses and the absence of 159 
medications except for parasitic control. The CKD group consisted of cats with 160 
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chronic kidney disease (n = 11) that had not been treated with any drugs in 161 
accordance with the clinician’s recommendations and had been kept on a renal 162 
diet formulated by a diplomat from the European College of Veterinary and 163 
Comparative Nutrition (ECVCN). The recruitment of these cats was based on 164 
the diagnosis performed by a clinician and on the guidelines for IRIS staging of 165 
chronic kidney disease.22 The third group (ACE, n = 5) included cats affected by 166 
CKD, which were being treated with the specific diet and the ACE inhibitor 167 
hydrochloride (dosage regime was adapted and based on the values commonly 168 
recommended in clinical animal practice), administered for at least 40 days 169 
prior to sample collection. The inclusion criteria for CKD cats were based on a 170 
stable CKD history (in at least two separate time points) entailing anamnesis, 171 
physical examination, measurements of blood creatinine and confirmation of 172 
low urine specific gravity (<1035).  173 
The inclusion criteria for all three groups were age (adult, centred on the 174 
mean age of the CKD cats) and Body Condition Score (BCS, 9 point scale, 175 
according to the American Animal Hospital Association, centred on the mean 176 
value for the CKD cats). 177 
The exclusion criteria were the following: pre-renal or post renal 178 
azotemia, acute renal injury, acute infections, feline lower urinary tract disease 179 
(FLUTD), systemic metabolic disease (e.g., hyperthyroidism), diabetes, heart 180 
failure and positivity for feline leukaemia virus (FeLV) or feline 181 
immunodeficiency virus (FIV). 182 
 183 
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Sampling  184 
Serum was collected and stored for 30 minutes at room temperature. 185 
Subsequently, it was separated by centrifugation (2500 g for 8 minutes) and two 186 
aliquots were obtained: one for the analysis of the biochemical and metabolic 187 
parameters, mainly related to the renal function, and one for the assessment of 188 
the carbonyl stress biomarkers, which constituted the target of the present 189 
study. Samples were stored at -80°C and analysed according to the procedures 190 
described in the following paragraphs. Urine samples were collected by 191 
cystocentesis when required by the clinician or by a non-invasive method 192 
(using a urine collection kit) and analysed within one hour by an automated 193 
analyser to obtain the urine protein to creatinine (UP/UC) ratio. Blood urea, 194 
(UREA), triglycerides (TG), potassium (K), phosphorous (P), creatinine (CREA) 195 
and total proteins (TP) were evaluated by an automated analyser. Plasma 196 
glucose (Glu) was determined in blood heparinised samples centrifuged within 197 
15 minutes after sample collection.  198 
Systemic arterial pressure (SAP) measurement was taken using an indirect 199 
Doppler method via the radial pulse with the cat sitting or in sternal 200 
recumbency. The recorded value is the mean of five measurements. 201 
 202 
Advanced end-products  203 
All samples were analysed in duplicate.  204 
Pentosidine (PENT) 205 
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Detection of pentosidine (PENT) was performed using high performance liquid 206 
chromatography (HPLC), according to Valle et al,24 using a Waters system 207 
(Waters S.P.A., Milan, Italy). Briefly, protein content, after delipidation with 208 
hexane and precipitation with trichloroacetic acid, was hydrolysed with 6 209 
mol/L hydrochloric acid for 18 h at 110°C in borosilicate screw-capped tubes, 210 
dried in a Speed-Vac concentrator and then reconstituted in HPLC-grade water 211 
containing 0.01 mol/L heptafluorobutyric acid (HFBA). Subsequently, it was 212 
filtered through a 0.45-µm pore diameter Ultrafree MC (Millipore, Milan, Italy) 213 
and injected into a Xterra C18 MS column (250 × 4.6 mm; Waters S.P.A., Milan, 214 
Italy) with a curvilinear gradient program of 20% – 40% methanol from 0 to 30 215 
min and containing water (MilliQ, Millipore, Milan, Italy); both water and 216 
methanol contained 0.01 mol/L HFBA as a counterion. The PENT peaks were 217 
monitored using a Waters 2475 fluorescent detector (excitation 335 nm and 218 
emission 385 nm). A PENT synthetic standard (prepared as described by 219 
Grandhee and Monnier25) was injected at the start of each run to determine 220 
PENT concentration in the sample using peak area comparison. The amount of 221 
PENT was expressed as pmol per mg of plasma protein content.  222 
Carboxymethyllysine (CML)  223 
Serum Carboxymethyllysine (CML) was evaluated by ELISA (EIAab, 224 
Wuhan, China), according to the manufacturer’s instructions as reported by 225 
Bruynsteen et al.26 The detection range of the CML ELISA kit was 0.78-50 ng/ml, 226 
therefore the serum samples were diluted 1:10. Absorbance was read at 450 nm 227 
using a microplate reader. The observed results were expressed as ng/ml. 228 
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Advanced oxidation protein products (AOPP)  229 
Determination of AOPP was based on spectrophotometric analysis 230 
according to Bruynsteen et al.26 AOPP concentration was measured by 231 
spectrophotometry on a microplate reader at λ 340 nm and was calibrated with 232 
a chloramine-T (CT) solution in presence of potassium iodide; briefly, 200 µl of 233 
serum (diluted 1:10 with PBS) were placed on a 96-well microtiter plate, and 20 234 
µl of acetic acid were added. In standard wells, 10 µl of 1.16 mol/L potassium 235 
iodide were added to 200 µl of CT solution (0–100 µmol/L) followed by 20 µl of 236 
acetic acid. The absorbance of the reaction mixture was immediately read at 340 237 
nm against a blank containing 200 µl of PBS, 10 µl of potassium iodide, and 20 238 
µl of acetic acid. The AOPP concentrations were expressed as µmol/L of CT 239 
equivalents. 240 
 241 
Carbonyls from the peroxidation cascade  242 
Malondialdehyde MDA 243 
Serum malondialdehyde was measured by HPLC according to the 244 
method published by Nielsen et al,27 with slight modifications. Briefly, aliquots 245 
of serum were mixed (volume/volume) with a 0.6% (w/v) aqueous solution of 246 
thiobarbituric acid (TBA). The mixture was acidified with 1/20 volume of 100% 247 
(w/v) trichloroacetic acid and heated at 100°C for 1 hour. The samples were 248 
then cooled in ice and centrifuged at 13.000 g for 5 minutes. Aliquots of 50 ul of 249 
the supernatant were injected into the HPLC system equipped with a Novapak 250 
C18 4µm 3.9x150 mm column (Waters S.P.A, Milan, Italy). The elution was 251 
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isocratic. The mobile phase consisted of a mixture of a 10 mM potassium 252 
dihydrogen phosphate solution, adjusted to pH 6.8 with KOH 1M, and 253 
methanol in a ratio of 60/40. The flow rate was 1 ml/min. Detection was 254 
performed by a spectrofluorometery (Ex/Em = 532/553 nm). Under our 255 
conditions, the peak of the MDA-TBA adduct was well resolved at a retention 256 
time of 4.8 min. 257 
MDA concentration (nmol/ml) was calculated in reference to a calibration curve 258 
of MDA sodium salt standard according to the methodology developed by Nair 259 
et al28. Concentration was expressed in nmol/ml.  260 
 261 
Hexanoyl-Lysine HEL 262 
Hexanoyl-Lys (HEL) was evaluated by ELISA (JalCA., Shizuoka, Japan), 263 
according to the manufacturer’s instructions. The detection range of the HEL 264 
ELISA kit was 2-700 nmol/L. After overnight incubation with alpha-265 
chymotrypsin, serum samples were ultrafiltered (cut-off 10kDa) and diluted 1:2. 266 
Absorbance was read at 450 nm. Results were expressed as nmol/mg protein. 267 
 268 
Carbonyl from the glycoxidation cascade  269 
Methylglyoxal MGO  270 
Methylglyoxal was evaluated according to the method proposed by Wild et al,29 271 
with slight modifications. The method is based on the reaction between N-272 
acetyl-L-cysteine (Sigma Aldrich) and methylglyoxal at room temperature. The 273 
reaction was performed in 100 mM sodium dihydrogen phosphate buffer 274 
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(adjusted to pH 7.0 with NaOH 10 M) at 22 °C. As the standard curve for the 275 
reaction, different concentrations of MG [???] (0.5, 1, 2, and 5 mM) were used. 276 
MG solutions (Sigma Aldrich) equating to 0.5, 2 and 5 mM were added to a 277 
volume of 980 μL with sodium dihydrogen phosphate. The reaction was started 278 
by adding 20 μL of 500 mM N-acetyl-L-cysteine and the absorption was 279 
recorded after 7 minutes. The condensation product, N-α-acetyl-S-(1-hydroxy-280 
2-oxo-prop-1-yl) cysteine was determined by recording the absorption at 288 281 
nm (UVIKON 923, Bio-Tek Instrument). Results were expressed as μmol/ml. 282 
 283 
Serum protein content determination 284 
Serum protein content was determined using the BCA protein assay kit 285 
according to the manufacturer’s instructions (Thermo Fisher Scientific., 286 
Rockford, IL, USA). 287 
 288 
 289 
Statistical analysis 290 
Data were analysed using GraphPad Prism for Mac ,version 7.00 (GraphPad 291 
Software, La Jolla California USA, www.graphpad.com). 292 
All measurements were performed in duplicate and data were expressed as 293 
medians and interquartile ranges. After checking for normality using the 294 
Kolmogorov-Smirnov test, comparisons between groups were performed using 295 
the Kruskal–Wallis test followed by Dunn's multiple‐comparison tests. P values 296 
<0.05 were considered significant (a “tendency” was considered for P < 0.1). 297 
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Relationships between plasma concentrations of the considered biomarkers and 298 
the other metabolic parameters were investigated using the one-tailed 299 
Spearman’s correlation coefficient (rS). 300 
 301 
Results 302 
Results are illustrated in Tables 1 and 2. Comparison of the groups showed a 303 
significant increase in Crea and Urea in CKD and ACE treated groups, 304 
compared with healthy (CG) cats (Table1). No statistically significant 305 
differences were found between groups for TP, GLU, TG and K. The highest 306 
concentration of P was found in the CKD group , whereas the ACE treated 307 
group showed intermediate values. In both CKD and ACE treated groups 308 
UP/UC was higher in comparison with the control group.  309 
 310 
Table1. Summary of laboratory findings for selected clinical parameters in CG, CKD and 311 
ACE treated cats, respectively. Data are reported as medians plus interquartile range 312 
(25th and 75th percentiles). Letters identify differences between group comparisons (P < 313 
0.05). 314 
 CG CKD ACE 
CREA 1.20a (1.05;1.48) 3.70b (1.89;6.0) 2.10b (1.95;3.40) 
UREA 42.0a (34.5;54.0) 73.0b (59.0;188.0) 125.0b (91.0;166.5) 
TP 6.20 (5.95;7.05) 6.30 (5.7;7.0) 6.80 (5.55;7.10) 
GLU 101.0 (99.0;103.5) 96.0 (83;107.0) 90.0 (79.0;120.0) 
TG 29.0 (23.0;49.0) 44.0 (37.0;45.0) 35.0 (28.0;48.50) 
K 4.30 (3.55;4.55) 4.90 (3.80;5.55) 4.50 (4.30;6.35) 
P 4.20a (4.0;5.65) 7.3b (5.15;8.0) 5.10ab (5.0;5.50) 
UP/UC 0.21a (0.20;0.27) 0.70b (0.40;0.74) 1.60b (1.10;3.10) 
SAP 145.0 (140.0;155.0) 150.0 (140.0;230.0) 155.0 (135.0;187.50) 
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CREA: creatinine (mg/dl); TP: total proteins (g/dl); GLU: glucose (mg/dl); TG: triglycerides 315 
(mg/dl); K: potassium (mEq/l); P: phosphorus (mEq/l); UP/UC: urine protein to creatinine ratio; 316 
SAP: systemic arterial pressure (mmHg). 317 
 318 
AOPP, MDA and HEL concentrations were significantly higher in CKD 319 
and ACE treated groups in comparison with the control (CG) group. When 320 
compared with CG, CML was higher in ACE, whereas CKD showed 321 
intermediate values. ACE treated groups were characterized by the highest 322 
values of CML, AOPP and HEL; conversely, the CKD group showed the highest 323 
concentration of MDA. The levels of PENT and MGO showed no statistical 324 
differences between groups (Tab.2).  325 
 326 
 327 
Table 2 Advanced glycated end-products and carbonyl compounds in CG, CKD and ACE 328 
cats. Data are reported as medians plus interquartile range (25th and 75th percentiles). 329 
Letters identify differences between group comparisons (P < 0.05) 330 
 331 
 CG CKD ACE 
CML 13.81a (11.64;19.46) 25.34 -(21.89;43.08) 42.85b (33.11;65.43) 
AOPP 83.61a (66.2;103.9) 189.3b (120.2;288.6) 247.1b (137.0;368.9) 
PENT 2.23 (0.63;5.77) 1.47 (1.09;4.33) 1.47 (1.28;3.89) 
MGO 360.90 (226.20;531.00) 283.40 (177.61;362.00) 261.00 (240.30; 370.70) 
MDA 4.85 a (3.80;8.79) 27.02b (17.74;48.85) 24.70b (15.42;58.21) 
HEL 0.26a (0.16;0.35) 0.88b (0.62;1.12) 1.26b (0.43;2.31) 
CML: carboxymethyllysine (ng/ml); AOPP: advanced oxidation protein products (µmol/L of CT 332 
equivalents/mg protein); PENT: pentosidine (pmol/mg protein); MGO: methylgyoxal (µmol/ml); 333 
MDA: malondialdehyde (nmol/ml); HEL: hexanoyl-lysine (nmol/mg protein). 334 
 335 
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Crea was positively correlated with CML (rs 0.49, P < 0.05), AOPP (rs 0.56, P < 336 
0.05), MDA (rs 0.47, p<0.05), and HEL (rs 0.50, p<0.05). It was also correlated with 337 
laboratory findings for selected clinical parameters as Urea (rs 0.79, P < 0.0001), P 338 
(rs 0.57, P < 0.05) and UP/UC (rs 0.64, P < 0.01). Urea was positively correlated to 339 
CML (rs 0.46, P < 0.05), AOPP (rs 0.62, P < 0.01), MDA (rs 0.72, P < 0.0001), and 340 
HEL (rs 0.56, P < 0.05), as well as to K (rs 0.52, P < 0.05) and UP/UC (rs 0.65, P < 341 
0.01).  342 
HEL was positively correlated with CML (rs 0.48, P < 0.05), AOPP (rs 0.76, P < 343 
0.0001), MDA (rs 0.90, P < 0.0001) and K (rs 0.60, P < 0.01).  344 
AOPP was positively correlated with CML (rs 0.56, P < 0.05), MDA (rs 0.75, P < 345 
0.0001), P (rs 0.48, P < 0.05) and UP/UC (rs 0.54, P < 0.05). 346 
MDA was positively correlated with K (rs 0.65, P < 0.01) and UP/UC (rs 0.54, P < 347 
0.01) and to CML (rs 0.36, P = 0.05). CML was negatively correlated with GLU (rs 348 
-0.482, P <0.05). MGO was negatively correlated with K (rs -0.574, P < 0.05). PENT 349 
was only positively correlated with SAP (rs 0.46, P < 0.05). 350 
The correlation table is provided as supplementary data. 351 
 352 
Discussion  353 
The present study focuses on hallmarks of oxidative stress and carbonyl stress in 354 
feline CKD. Significantly higher concentrations of intermediates and "end 355 
products" of carbonyl/oxidative stress, which are also uremic toxins, were 356 
detected in nephropathic cats.  357 
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An increased concentration of creatinine and urea and an increase in the urine 358 
protein to creatinine ratio (UP/UC, indicating proteinuria associated with kidney 359 
disease, provided that pre-renal and post-renal causes are excluded) were 360 
observed in CKD and ACE treated cats. ACE inhibitors, like benazepril, have 361 
been shown to reduce proteinuria in cats30; however, in the present study, UP/UC 362 
in the ACE treated group was even higher than in the other group. The late 363 
initiation of the therapy (introduced 40-60 days before sample collection) can 364 
probably explain such a difference. 365 
Over 100 substances have been classified as uremic toxins by the European 366 
Uremic Toxin (EUTox) Work Group20 and recent studies have thoroughly 367 
categorised these different molecules. Urea and creatinine are the most common 368 
uremic toxins that can increase in cats with CKD and, as expected, in our study 369 
both of them increased in the cats with CKD. These compounds are soluble in 370 
water, have low molecular weights, and are classified by EUTox as the most 371 
reliable biomarkers for the evaluation of renal failure.31 Not surprisingly, in our 372 
study, Urea and Crea showed a positive correlation with each other as well as 373 
with UP/UC. In fact, an increase in these parameters typically occurs in CKD cats, 374 
and it is used as a diagnostic tool according to the IRIS staging of CKD22. 375 
However,  several other metabolites, other than these compounds, 376 
contribute to the toxic environment caused by the disease.31 Their concentrations 377 
provide insight into the clinical severity of CKD and favour the maintenance of 378 
both oxidative and carbonyl stress in a vicious circle. 379 
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In addition, Crea and Urea positively correlated with CML, AOPP, MDA and 380 
HEL, confirming an association with two recognized markers of renal failure in 381 
feline medicine. In particular, a statistically significant increase of CML, AOPP, 382 
HEL and MDA was found in the cats affected by CKD. By contrast, they showed 383 
a negligible increase in PENT and MGO. These differences were also consistently 384 
observed in the ACE treated group. 385 
AOPP are a cluster of oxidative products derived from proteins and are 386 
recognised as markers of protein oxidative damage and of inflammation severity. 387 
The injured proteins are generated through a mechanism involving free radical 388 
direct oxidation of amino acids (e.g., tyrosine (Tyr), lysine (Lys), proline (Pro), 389 
arginine (Arg), etc.) (Dean et al 1997 [This should be added to the References]), 390 
and as an indirect consequence of lipoperoxidation. 391 
AOPP are also defined as "accumulated solutes, normally excreted by the 392 
kidneys, that interact negatively with biological functions”.15 393 
It has been reported that serum AOPP concentration (closely correlated with 394 
other markers) increases with the progression of chronic diseases.32,33 395 
Accumulation of plasma and renal AOPPs is a common pathologic finding in 396 
human patients with CKD.34 Witko-Sarsat et al32,33 showed that in vivo levels of 397 
AOPP correlated well with creatinine clearance.  398 
In human studies of uremic patients, the concentration of plasma AOPP is related 399 
to the oxidative activity of circulating neutrophils, suggesting that these 400 
leukocytes might be involved in plasma AOPP formation through the 401 
myeloperoxidase/H2O2 system. In agreement with this hypothesis, Keegan and 402 
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Webb10 reported that the neutrophil oxidative burst is higher in chronic renal 403 
failure. Moreover, recent studies showed alterations in neutrophil oxidative 404 
metabolism and oxidative stress in dogs with CKD.35–39 405 
Neutrophils can, therefore, be a source of pro-oxidant molecules contributing to 406 
an abnormal production of ROS and participating to the formation of AOPPs. 407 
Neutrophil oxidative metabolism can, in turn, be activated by other uremic 408 
toxins.39 409 
In accordance with the above mentioned findings, our study demonstrates for 410 
the first time a significant increase in AOPP in cats. In fact, when compared with 411 
control animals, CKD and ACE treated cats showed a 77% and 132% increase, 412 
respectively, in this parameter. AOPP are good hallmarks of the progression of 413 
chronic renal failure and the severity of uremia;40 accordingly, in our study their 414 
concentrations correlated well with those of creatinine and urea. As previously 415 
reported, they are also a good and accurate biomarker of oxidative stress,41 and 416 
in the present study significant correlations with other markers of 417 
lipoperoxidation were found (CML, MDA, HEL).  418 
Serum MDA [???] is an organic and very simple compound and one of the highly 419 
reactive carbonyls originating from PUFA oxidation (in particular from 420 
peroxidation of arachidonic, eicosapentaenoic and docosahexaenoic acid).42 In 421 
humans, it is the most abundant product, since it comprises 70% of all the 422 
carbonyls obtained by lipid peroxidation.18 423 
In this study, serum MDA consistently increased in CKD (284%) and in ACE 424 
treated (256%) cats. An increase in serum MDA was previously observed in CKD 425 
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cats by Yu and Paetau-Robinson9 and four weeks of antioxidant supplements did 426 
not exert any effect on this parameter. 427 
MDA correlates with AOPP, HEL and with other markers of CKD (creatinine, 428 
urea, Potassium and PU/CU): the remarkably high correlation with HEL (r = 429 
+0.904) is explained by their shared origin from lipid peroxidation.  430 
Since potassium did not vary significantly between groups but it often varies in 431 
CKD cats43 according to diet intake, the positive correlation with MDA is 432 
probably suggestive of an increased oxidative stress in cats with higher 433 
potassium quartiles, although still in the normal range.  434 
Hexanoyl-lysine (HEL) is a recently discovered lipid peroxidation biomarker 435 
derived from the oxidation of omega-6 unsaturated fatty acids.14 HEL is formed 436 
when a lipid hydroperoxide links to a lysine residue, forming a stable 437 
compound.44 Arachidonic acid is one of the PUFA that, after oxidation, gives rise 438 
to MDA and HEL compounds;42 it is often added to cat food, especially during 439 
growth, gestation and lactation, because these animals are unable to synthesize 440 
it.45 441 
The actual estimated requirements, based on a low reported synthesis capacity, 442 
is 8 mg/100 g dry matter [???] (DM), considering a metabolic energy requirement 443 
(MER) of 75 kcal/kg0,67[???] in adult animals and 20 mg/100 g DM during growth 444 
and reproduction46. Arachidonic acid is naturally present in animal tissues, so it 445 
does not have to be added to food containing proteins of animal sources.45 446 
When compared with control cats, CKD and ACE treated cats showed highly 447 
significant increases in serum HEL (three times higher than controls in the CKD 448 
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group and five times higher than controls in ACE cats). Therefore, it would be 449 
interesting to evaluate whether a high content of arachidonic acid in the diet of 450 
CKD cats might generate oxidants and promote oxidative stress, as observed in 451 
CKD disease; if that were the case, more attention should be paid to the total 452 
amount of this substance provided to cats, in particular to those affected by CKD. 453 
The diet should be balanced with an equivalent amount of antioxidants to avoid 454 
the increase of carbonyls, such as MDA and HEL, originating from the 455 
peroxidation cascade.  456 
CML is formed during the Maillard reaction by a process of glycoxidation. 457 
It can derive from different compounds, such as aldoses, ketoses, ascorbate, 458 
PUFAs and other molecules, and it is classified as an advanced glycation-459 
lipoxidation end-product (AGE). Another relevant source of CML is from food. 460 
It is found in dairy products, but also in meat, fish, cereal-derived products, and 461 
in a group of fruit and vegetables that have been cooked or treated in an 462 
industrial context.16 463 
As previously shown47, CML increases in uremic patients and such an 464 
increase is also generally paralleled by increased levels of PENT,47 since they 465 
share the same molecular origin. In the present study, CML levels increased 3-466 
fold in the ACE treated group and doubled in the CKD group, but, intriguingly, 467 
a correlation with PENT was not observed. 468 
We might hypothesize that although CML mainly derives from the 469 
peroxidation cascade, diet may also play a noteworthy role. Hull et al48 showed 470 
that the CML content of cat food can be high. High exposure to CML should be 471 
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taken into careful consideration because this compound could be hazardous for 472 
feline health. This is even more true in cats with CKD, since CML seems to be 473 
associated with degenerative disorders and chronic kidney diseases.49 474 
Interestingly, CML levels are positively correlated with markers of kidney 475 
function, such as Crea and Urea, and negatively correlated with serum glucose, 476 
indicating that, in cats, high glucose might not lead to the formation of AGEs 477 
through the Maillard reaction. Other significant correlations were found with 478 
HEL (P < 0.05) and AOPP (P < 0.05), which can therefore be included, as is the 479 
case for humans, in the array of toxins found in uremic cats. 480 
Methylglyoxal is generated by a series of metabolic pathways, mostly belonging 481 
to the glycolytic process. It is an important precursor of advanced glycation end 482 
products, being a highly powerful glycating agent. It is also involved in diabetic 483 
microvascular complications.50 Increases in MGO have been observed during 484 
hyperglycaemia as well as in the uremic state.  485 
In our study, MGO was not significantly different between the three groups of 486 
cats. Therefore, we can hypothesize that, in contrast to what has been observed 487 
in humans [perhaps a reference should be added here], the glycation pathway 488 
does not play a role in the pathophysiology of uremia in cats. 489 
Pentosidine is a well-known advanced glycation end product and a uremic toxin, 490 
that, surprisingly, the levels of which were not, surprisingly,  significantly 491 
different in the three groups of our study. This finding differs from what has been 492 
reported in human patients affected by CKD. In these cases a marked increase of 493 
pentosidine was found and also associated with a low glomerular filtration rate, 494 
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oxidative stress and inflammation.51–53 In our opinion, in feline CKD, lipids and 495 
lipoperoxidation seem to play a more important role than glucose, glycation or 496 
glycoxidation, which seem to be unrelated to this disease. In cats, a distinct 497 
pathway for the formation and accumulation of uremic toxins should be 498 
considered, along with different uremic oxidative stress compounds. In line with 499 
this reasoning, PENT might turn out to be a minor end product in the bulk of 500 
AGEs. 501 
In addition, in our groups of cats, PENT does not correlate with other carbonyl 502 
determinations and other clinical parameters, although it does with SAP. We can 503 
hypothesize that, in cats, pentosidine accumulation is, as in humans: age related: 504 
connected with the progression of renal failure: and occurring mainly in tissues 505 
rather than in blood. Tissue accumulation of PENT is well described in humans 506 
and in other animals such as rats with CKD (where it accumulates in the 507 
tubules),54 dogs, rabbits, monkeys, etc. Moreover, in cats with CKD, an interstitial 508 
fibrosis has been observed.55 Pentosidine accumulation may occur in the kidneys 509 
or in the artery walls, contributing to an increase in blood pressure. It is 510 
noteworthy that, in humans, serum pentosidine is positively associated with 511 
arterial stiffness and thickness.56 Further studies are needed to evaluate this 512 
intriguing hypothesis. 513 
According to our results, the use of ACE inhibitors exerted a negligible effect on 514 
the carbonyl oxidative stress status. By contrast, Monacelli et al23 reported, in 515 
humans, that valsartan, an angiotensin II receptor antagonist, besides having 516 
antihypertensive activity, is also effective in scavenging oxidative stress species. 517 
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However, some differences between the present study and that of Monacelli et 518 
al23 should be considered. Our experimental animals only received the therapy 519 
for 40-60 days, while the trial reported by Monacelli et al23 lasted 6 months. The 520 
difference in the duration of the treatment may explain the lack of efficacy 521 
reported in our study. Such a difference could also be due to the use of a different 522 
type of drug. In fact, in our experiment cats were treated with benazepril, an 523 
angiotensin-converting-enzyme inhibitor, whereas in the study carried out by 524 
Monacelli et al23, human patients received valsartan, an AT1 antagonist.  525 
Although carefully designed, our study suffers from some limitations, mainly 526 
due to its small sample size. In particular, it would have been more appropriate 527 
to enrol a larger number of cats for each IRIS stage (from 1 to 4) in order to draw 528 
more valid conclusions. The progression of uremic toxin production and/or the 529 
existence of a CKD threshold for their formation is also a matter of debate and 530 
deserves further investigation. Even if we had just included cats fed a renal diet, 531 
we would still have had confounding effects. In fact, renal diets of different 532 
brands can also vary in terms of omega 3-6, protein, phosphorus and carbonyl 533 
content. Further studies focusing on the intake of single diet components are 534 
required. 535 
 536 
Conclusions  537 
To the best of our knowledge, this is the first study to take into account 538 
contemporaneously several uremic toxins - according to the EUTox database - 539 
and biochemical parameters in cats affected by CKD. Evidence of strong carbonyl 540 
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stress is confirmed in CKD cats, irrespective of the therapy with ACE inhibitors. 541 
These toxic molecules contribute to maintaining and promoting oxidative stress 542 
and facilitate the progression of systemic damage. However, two markers 543 
Pentosidine and Methylglioxal remained unaffected. This phenomenon suggests 544 
some hypotheses that need to be verified and, at the same time, raises the 545 
possibility that the disease might be characterized by a new pattern of markers. 546 
The significant and striking increases in CML and HEL offer challenging 547 
possibilities in terms of specific diets aimed at the prevention of kidney disease. 548 
Currently, more studies are needed to clarify the disease mechanisms and their 549 
associations with clinical signs, cellular damages and kidney malfunction in 550 
affected cats.  551 
The results of the present study broaden our understanding of this widespread 552 
problem afflicting feline health and help pave the way towards new research 553 
fields required to make substantial progress in clinical veterinary practice. 554 
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Figure 1. NB note misspelling of “pathways” in top left box. 740 
 741 
Figure 1. The vicious cycle of Reactive Carbonyl Species (RCS) and Reactive Oxygen Species (ROS) 742 
formation pathways. AGEs: advanced glycation end products; ALEs: advanced lipoxidation end products; AOPP: 743 
advanced oxidation protein products; aa: amino acids  744 
 745 
